Zobrazeno 1 - 10
of 75
pro vyhledávání: ''
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Autor:
Kentaro Ito, Kazutaka Kakinuma, Tadashi Sakaguchi, Naoya Hida, Masamichi Mineshita, Osamu Hataji, Kei Morikawa, Takeo Inoue, Yuko Komase, Naoki Furuya
Publikováno v:
Oncology
Objectives: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in p
Autor:
Chia Che Wu, Meng Che Hsieh, Cheng-Hua Huang, Shih Yu Huang, Harvey Yu-Li Su, Po Hui Chiang, Chun-Chieh Huang, Kun Ming Rau, Jui Ming Liu, Hao Lun Luo, Ming Tse Sung
Publikováno v:
Oncology. 98:146-153
Objectives: Platinum-based chemotherapy is the standard treatment for metastatic urothelial carcinoma (mUC). However, considering elderly patients often experience comorbidities and frailty, the utility of cisplatin-based chemotherapy for elderly pat
Autor:
Takamichi Komori, Masaaki Motoori, Kazumasa Fujitani, Susumu Miyazaki, Yasuhiro Miyazaki, Norihiro Matsuura, Hisateru Komatsu, Kazuhiro Iwase, Yujiro Nishizawa, Akira Tomokuni
Publikováno v:
Oncology. 98:29-34
Purpose: Neoadjuvant chemotherapy (NAC) followed by surgery is a promising treatment strategy for patients with advanced gastric cancer. Severe toxicity associated with the treatment may reduce the dose intensity of chemotherapy, resulting in the eff
Autor:
Nicolas Magné, Jean-Phillipe Jacquin, Pauline Doucey, Elise Rowinski, Benoîte Méry, Xavier Simoens, Alexis Vallard
Publikováno v:
Oncology. 97:1-6
Background: Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy i
Autor:
Kenichi Yoshimura, Mitsunori Morita, Naoyuki Sone, Yoshinori Hasegawa, Chikara Sakaguchi, Toshihiko Kaneda, Tetsuo Noguchi, Takashi Niwa, Hiroshige Yoshioka, Masataka Hirabayashi, Toyohiro Hirai, Toshihide Yokoyama, Satoshi Ikeda, Yasutaka Nakano, Chihito Komaki, Tadashi Ishida, Hiromi Tomioka
Publikováno v:
Oncology. 97:327-333
Background: There has been no study so far on gemcitabine continuous maintenance therapy targeting only squamous non-small-cell lung cancer (NSCLC) patients. This study aimed to assess the efficacy and safety of cisplatin plus gemcitabine followed by
Autor:
Tsunekazu Mizushima, Chu Matsuda, Masaki Mori, Ichiro Takemasa, Naotsugu Haraguchi, Hidekazu Takahashi, Junichi Nishimura, Taroh Satoh, Daisuke Sakai, Toshihiro Kudo, Tsuyoshi Hata, Taishi Hata, Yuichiro Doki
Publikováno v:
Oncology. 97:211-216
Objectives: The aim of this study was to determine the recommended dose (RD) of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer. Method: Patients received
Autor:
Mariela A. Blum Murphy, Irene Thomas, Jane E. Rogers, Elizabeth Sanders, Jaffer A. Ajani, Fatemeh G. Amlashi, Namita Shanbhag, Lianchun Xiao, Elena Elimova
Publikováno v:
Oncology. 96:252-258
Background: The RAINBOW trial established ramucirumab combined with paclitaxel as a second-line option in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Ramucirumab was given on days 1 and 15 with paclitaxel on days 1, 8, and
Autor:
Takanori Hirai, Takeshi Hiramatsu, Shinya Maruta, Eizaburo Ohno, Kuroiwa M, Hiroshi Matsubara, Takuya Ishikawa, Masashi Hattori, Tomoyuki Tsuzuki, Koichi Achiwa, Hajime Sumi, Yoshiki Hirooka, Akira Kanamori, Yoji Sasaki, Koji Nonogaki, Masahiko Ando, Hiroki Kawashima, Senju Hashimoto
Publikováno v:
Oncology. 96:1-7
Objective: To evaluate the efficacy and safety of alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. Methods: Patients with histologically proven, unresecta
Autor:
Kyung Sik Kim, Kyoo Ho Shin, Hyo Song Kim, Hyung Soon Park, Hyuk Hur, Jee Hung Kim, Young Deuk Choi, Sang Kyum Kim, Sun Young Rha, Jung Woo Han, Sung Hoon Noh, Sunghoon Kim, Su Jin Heo, Young Han Lee, Hyun Cheol Chung, Seung Hyun Kim, Joong Bae Ahn, Jin Suck Suh
Publikováno v:
Oncology. 96:59-69
Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or g